Aptevo Therapeutics Stock Set to Reverse Split on Tuesday, December 30th (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s stock is going to reverse split before the market opens on Tuesday, December 30th. The 1-18 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 29th.

Aptevo Therapeutics Price Performance

Shares of APVO stock traded down $0.32 during trading hours on Friday, hitting $0.61. The stock had a trading volume of 14,545,851 shares, compared to its average volume of 2,281,441. The firm has a market capitalization of $10.23 million, a PE ratio of -0.01 and a beta of 1.41. The stock’s 50 day moving average is $1.30 and its 200 day moving average is $2.02. Aptevo Therapeutics has a twelve month low of $0.50 and a twelve month high of $109.80.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.14). As a group, equities analysts predict that Aptevo Therapeutics will post -15.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on APVO shares. Zacks Research upgraded shares of Aptevo Therapeutics to a “hold” rating in a report on Thursday, September 18th. Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday. Finally, Roth Capital upgraded Aptevo Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aptevo Therapeutics currently has a consensus rating of “Hold”.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent filing with the SEC. 8.06% of the stock is owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.